Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 38 Publications

6 Customer Reviews

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MYrDfZRwfG:6aXOgRZN{[Xl? MXi3NkBp M{fXcmROW09? NYW0UYFNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> M1TsU|I1QTByMk[2
DU145 MmrHR5l1d3SxeHnjJGF{e2G7 MmHVO|IhcA>? NFTjW5FFVVOR MoLQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP MYGyOFkxODJ4Nh?=
A2780 NXjNOnRXS3m2b4TvfIlkKEG|c3H5 M1W5TVczKGh? NXL1bHozTE2VTx?= NHrP[otEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN MlyxNlQ6ODB{Nk[=
U87MG NUDtZ|FXS3m2b4TvfIlkKEG|c3H5 M1rZVVczKGh? NWjCZXpzTE2VTx?= M4KybWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= M13t[|I1QTByMk[2
A2780 NI[4WJFHfW6ldHnvckBCe3OjeR?= NHfYTWIyKGh? MnP4SG1UVw>? MlfDTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkC1OUDPxE1? M3;LTFI1QTByMk[2
DU145 MlfrSpVv[3Srb36gRZN{[Xl? NYTBd2dFOSCq M4W0UGROW09? M{HzW2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBFXTF2NTDj[YxteyCqYYLic5JqdmdiTFvCNUBufXSjdHnvckB4cXSqIFXDOVAhd2ZiMD6wO|Mh|ryP NHr3Z2kzPDlyMEK2Oi=>
A2780 NHXuRXRHfW6ldHnvckBCe3OjeR?= NIPVN20yKGh? NUm0b2F[TE2VTx?= MmnCTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiRVO1NEBw\iByLkC3OEDPxE1? NXzibmR3OjR7MECyOlY>
MCF7 MYTGeY5kfGmxbjDBd5NigQ>? NID1SpAyKGh? NVzhWmwxTE2VTx?= M13O[2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>? M2HjSlI1QTByMk[2
U87MG MoHESpVv[3Srb36gRZN{[Xl? NF;qZpMyKGh? MYjEUXNQ NV3uPGwzUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= MlToNlQ6ODB{Nk[=
A2780 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13sNVczKGh? MVXEUXNQ M1W5ZWVEPTB;MD61NkDPxE1? M3uwVlI1QTByMk[2
SKMES-1 MofkR5l1d3SxeHnjJGF{e2G7 MX2xJO69VQ>? MXe3NkBp M{PRTGlv\HWlZYOgZ4VtdCCmZXH0bC=> NGm3S5kzPjBzM{OxPC=>
H596 MWDGeY5kfGmxbjDBd5NigQ>? NX:yZpNzOSEQvF2= NXXYUoRiUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= M2LhPVI3ODF|M{G4
HCC2450 NGjoOXZHfW6ldHnvckBCe3OjeR?= NXG4cJhwOSEQvF2= NWP2U48yUW2yYXnyd{Bk\WyuIHnueoF{cW:w NWi3eI1ROjZyMUOzNVg>
A549 M3\SSGZ2dmO2aX;uJGF{e2G7 MX61NFAhdk1? MWC0PEBp NEHKSFNFVVOR MorYTY5pcWKrdIOgRYt1KGGldHn2ZZRqd25? M4HR[|I2QTN5Mkm5
A549 M2fiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfYOVIyKM7:TR?= M1;Yb|czKGh? NWfBe5cxTE2VTx?= NHTvV|JKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NGDUWZYzPTl|N{K5PS=>
H522 NHr4SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxJO69VQ>? NVPIO5QxPzJiaB?= MofpSG1UVw>? MVnJcohq[mm2czDj[YxtKGe{b4f0bC=> MlfCNlU6Ozd{OUm=
LNCaP M1HnTGZ2dmO2aX;uJGF{e2G7 NGrw[GEyKM7:TR?= MXrTeZBxemW|c3XzJJAuSUuWIHzleoVtew>? NVyzem1XOjV|NkC3PVk>
LNCaP95 Mlj3SpVv[3Srb36gRZN{[Xl? MYWxJO69VQ>? MUfTeZBxemW|c3XzJJAuSUuWIHzleoVtew>? M{nJU|I2OzZyN{m5
HCT-15 NWHyOoxOSXCxdH;zbZMhSXO|YYm= Ml7vNVAh|ryP MXO0PEBp MlTxSG1UVw>? MVnJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUWgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? M1\hT|I2OTV{MkS1
HCT-116 MY\BdI91d3OrczDBd5NigQ>? MUixNEDPxE1? MnXTOFghcA>? NHnaZ5RFVVOR M3e3Smlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M3GzV|I2OTV{MkS1
NCI-H460 MVzBdI91d3OrczDBd5NigQ>? MXuxNEDPxE1? MlvJOFghcA>? NXjHW3FyTE2VTx?= NY\IfHppUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> MVSyOVE2OjJ2NR?=
SKOV-3 M4rKNmFxd3Sxc3nzJGF{e2G7 MmixNVAh|ryP MkfSOFghcA>? NEf0NZZFVVOR MUnJcoR2[2W|IHHwc5B1d3OrczDpckBUU0:YLUOgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? MUeyOVE2OjJ2NR?=
BSY-1 NF7DOXpCeG:2b4Ppd{BCe3OjeR?= NFHZRXUyOCEQvF2= NXS5cY1RPDhiaB?= Mn\OSG1UVw>? NFznS4lKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MXWyOVE2OjJ2NR?=
MKN-1 MoDKRZBwfG:|aYOgRZN{[Xl? MVOxNEDPxE1? MWS0PEBp M4TISGROW09? M3zic2lv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NHzid2YzPTF3MkK0OS=>
NCI-H522 NUDobGx4SXCxdH;zbZMhSXO|YYm= M3niTFExKM7:TR?= NFHWZVk1QCCq NYDXT3poTE2VTx?= NXT0TGI6UW6mdXPld{BieG:ydH;zbZM> M1j3VVI2OTV{MkS1
OVCAR-3 MVHBdI91d3OrczDBd5NigQ>? NVjSdHFxOTBizszN M4TadVQ5KGh? MnzHSG1UVw>? MXfJcoR2[2W|IHHwc5B1d3Orcx?= NXnqTlZJOjVzNUKyOFU>
HBC-5 MXvBdI91d3OrczDBd5NigQ>? NG[5RYYyOCEQvF2= MUO0PEBp M3TLdGROW09? NH7GT4VKdmS3Y3XzJIFxd3C2b4Ppdy=> MVeyOVE2OjJ2NR?=
RXF-631L MnTLRZBwfG:|aYOgRZN{[Xl? NGDac3UyOCEQvF2= M3rWOlQ5KGh? NF7QNYFFVVOR MlG3TY5lfWOnczDhdI9xfG:|aYO= NEXKPIszPTF3MkK0OS=>
MKN-45 M4j5bWFxd3Sxc3nzJGF{e2G7 NEDXTWgyOCEQvF2= MVq0PEBp NXrye2xWTE2VTx?= MXXJcoR2[2W|IHHwc5B1d3Orcx?= M{PHW|I2OTV{MkS1
BON-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofZOVAxKG6P MlXJNVAh\A>? Ml3SSG1UVw>? MXvJcohq[mm2czDj[YxtKGe{b4f0bC=> M{\RbFI2ODJ4Mkmy
BON-1 NEHsNlVHfW6ldHnvckBCe3OjeR?= Ml3WOVAxKG6P MX[0JIg> MWfEUXNQ M{jBT2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= NUPxPIhpOjVyMk[yPVI>
QGP-1 MVjGeY5kfGmxbjDBd5NigQ>? NV;SXVhJPTByIH7N M2DrR|QhcA>? NEi3UZFFVVOR MUTJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| MUeyOVAzPjJ7Mh?=
Huh7 MYjGeY5kfGmxbjDBd5NigQ>? NU\5R|hyOSEQvF2= NUS4cZpXOSCq NH\ze5BFVVOR MWrJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? Ml7UNlUxODR2MEO=
BNL M3vzbWZ2dmO2aX;uJGF{e2G7 MYqxJO69VQ>? NG\PZpQyKGh? MoPWSG1UVw>? Ml3xTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3 NF7vfWIzPTByNESwNy=>
MDA-MB-175 MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxJO69VQ>? NFXiS|Y2KGR? M4TaN2ROW09? M13zRmlEPTB:MTFOwG0> NUTmXI1TOjR6N{m3PVY>
MDA-MB-134 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxJO69VQ>? MUW1JIQ> MX7EUXNQ NFvKR3NKSzVyPEGg{txO NWPycpJnOjR6N{m3PVY>
HCC1500 NYDrToRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrkSlIyKM7:TR?= M1vDeVUh\A>? NVu3eHJITE2VTx?= MlTaTWM2ODxzIN88US=> NVzl[Vg{OjR6N{m3PVY>
EFM-19 NVLtfWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHpdXAyKM7:TR?= MlfhOUBl MVzEUXNQ NULzUJhYUUN3MEyxJO69VQ>? MXqyOFg4QTd7Nh?=
ZR-75-30 M1PSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT4OZUzOSEQvF2= NVHqW3BUPSCm M3vKeWROW09? MVXJR|UxRDFizszN M3LP[|I1QDd7N{m2
MDA-MB-361 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX1UncyKM7:TR?= NXvGepRCPSCm NWixPZV{TE2VTx?= NV7KeZduUUN3MEyxJO69VQ>? M1exd|I1QDd7N{m2
T-47D MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\YbocyKM7:TR?= NVTrNmVoPSCm NXT4SlRwTE2VTx?= NGDzNHhKSzVyPEGg{txO Mnv0NlQ5Pzl5OU[=
SK-BR-3 M2nxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojONUDPxE1? NXvQPIhSPSCm MUfEUXNQ MXzJR|UxRDFizszN NGTYcXUzPDh5OUe5Oi=>
UACC-732 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\jdHpkOSEQvF2= MXi1JIQ> MXjEUXNQ MlrCTWM2ODxzIN88US=> MVKyOFg4QTd7Nh?=
BT-474 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6xJO69VQ>? MYG1JIQ> NX71OHlRTE2VTx?= Ml;yTWM2ODxzIN88US=> MoHXNlQ5Pzl5OU[=
HCC202 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2wXI8yKM7:TR?= M3jPTFUh\A>? MoPNSG1UVw>? MXnJR|UxRDFizszN NED5boQzPDh5OUe5Oi=>
MCF7 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HRWFEh|ryP NIS3TY02KGR? M4DxSGROW09? NFvWZ3NKSzVyPEGg{txO M2LofVI1QDd7N{m2
MDA-MB-415 M1[2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3frdlEh|ryP M{PJNlUh\A>? NFKxVZlFVVOR NF[yPWZKSzVyPEGg{txO NWTTfXV[OjR6N{m3PVY>
MDA-MB-453 M3S1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHvTY8yKM7:TR?= MkHxOUBl NHrV[mZFVVOR MWDJR|UxRDFizszN NWPydm51OjR6N{m3PVY>
ZR-75-1 M4\wW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexJO69VQ>? NEC1fIY2KGR? NXTNOpRMTE2VTx?= Ml;1TWM2ODxzIN88US=> MlTJNlQ5Pzl5OU[=
HCC38 M4rGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuxJO69VQ>? NEXT[GM2KGR? NIn4b5VFVVOR MVPJR|UxRDFizszN MVGyOFg4QTd7Nh?=
HCC1419 NG\5bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv3V|ZkOSEQvF2= M3z0blUh\A>? Ml3qSG1UVw>? MnmzTWM2ODxzIN88US=> M13tcVI1QDd7N{m2
UACC-812 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xJO69VQ>? MXm1JIQ> Mme0SG1UVw>? NEXMTXdKSzVyPEGg{txO MVeyOFg4QTd7Nh?=
HCC1187 M2PISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T6OVEh|ryP NILr[HU2KGR? M1vzcmROW09? M3OxV2lEPTB:MTFOwG0> NXW1RZVqOjR6N{m3PVY>
KPL-1 M{i1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxJO69VQ>? M3zoNlUh\A>? MX;EUXNQ NGDDS4hKSzVyPEGg{txO MYSyOFg4QTd7Nh?=
SUM-225 M2i3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuxJO69VQ>? MnziOUBl NIq0UnFFVVOR NGK5SXNKSzVyPEGg{txO NIjCNJIzPDh5OUe5Oi=>
EFM-192A MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK4[oxVOSEQvF2= NV;LZnI3PSCm MYLEUXNQ M3vYZmlEPTB:MTFOwG0> NEe0e2QzPDh5OUe5Oi=>
JIMT-1 M2f4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfPNUDPxE1? NIn0RmY2KGR? NHHzNGdFVVOR Mm\LTWM2ODxzIN88US=> MYSyOFg4QTd7Nh?=
HCC1143 M4\yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTsNW1ROSEQvF2= NV2wNphOPSCm NV\QfFNSTE2VTx?= NYfSN4xuUUN3MEyxJO69VQ>? M4jjflI1QDd7N{m2
HCC2218 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET0SVYyKM7:TR?= NVLtRlhUPSCm NXO5NXdsTE2VTx?= Ml;qTWM2ODxzIN88US=> MkK5NlQ5Pzl5OU[=
MDA-MB-468 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzMNUDPxE1? Mn\SOUBl MlzLSG1UVw>? M2jKbWlEPTB:MTFOwG0> NF7EZpczPDh5OUe5Oi=>
BT-20 M3u3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOxJO69VQ>? MlXQOUBl M4\qcmROW09? M2nUcGlEPTB:MTFOwG0> MnzoNlQ5Pzl5OU[=
MDA-MB-435 NWPrepVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSxJO69VQ>? MkLXOUBl MXrEUXNQ NH24d3FKSzVyPEGg{txO MXOyOFg4QTd7Nh?=
BT-549 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PCUlEh|ryP NVOxeVBzPSCm MVfEUXNQ M1HQN2lEPTB:MTFOwG0> M{LxTlI1QDd7N{m2
HCC1806 M3vhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvMS2hPOSEQvF2= M{jiVFUh\A>? NVPSZ5IzTE2VTx?= MnS0TWM2ODxzIN88US=> M1O5SFI1QDd7N{m2
HCC1937 NVLkXHV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xJO69VQ>? MUi1JIQ> NIfnR5hFVVOR NYDOTpdDUUN3MEyxJO69VQ>? NYDRSWl4OjR6N{m3PVY>
Hs578T M4[zRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexJO69VQ>? M2HiW|Uh\A>? MWHEUXNQ MV;JR|UxRDFizszN NHLrcJUzPDh5OUe5Oi=>
LN18 M4C5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfERYYzOCEQvF2= MoHoO|IhcA>? MmjuSG1UVw>? MUDJR|UxRDVizszN MlTaNlQ4PDFyN{S=
LN229 NXLHfW8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXlOFVVOjBizszN MVq3NkBp NEfhWJJFVVOR M1nncWlEPTB:NTFOwG0> MYOyOFc1OTB5NB?=
LNZ308 M3uyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3bYd5OjBizszN M37MOVczKGh? NE\lNlRFVVOR MlvyTWM2ODx3IN88US=> M13w[VI1PzRzMEe0
T98G M3fF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmyNEDPxE1? NH\LRZI4OiCq NH\U[4tFVVOR NEHHempKSzVyPEWg{txO MlfWNlQ4PDFyN{S=
U87 NIK2UW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rMPFIxKM7:TR?= M3LSVVczKGh? NEHkWGdFVVOR MnfqTWM2ODx3IN88US=> MojVNlQ4PDFyN{S=
LN18 MmT0SpVv[3Srb36gRZN{[Xl? MnmxOUDPxE1? M2Xkd|I1KGh? M1XCW2ROW09? NYixclRzUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MoXpNlQ4PDFyN{S=
LNZ308 NHr0UoFHfW6ldHnvckBCe3OjeR?= Mn\pOUDPxE1? M4TWN|I1KGh? MmHxSG1UVw>? NFTL[odKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW NIW3WnEzPDd2MUC3OC=>
Saos-2 MVTGeY5kfGmxbjDBd5NigQ>? MYW1NEDPxE1? NXPzUHRHPDhiaB?= NH6yd3hKdmirYnn0d{Bk\WyuIHnueoF{cW:w MmT3NlQ4Ojd4NkC=
MG-63 MWHGeY5kfGmxbjDBd5NigQ>? MlK2OVAh|ryP MkL1OFghcA>? NY\hVndrUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MWWyOFczPzZ4MB?=
SJSA-1 NH3J[HlHfW6ldHnvckBCe3OjeR?= NXn4[JB3PTBizszN M1vvO|Q5KGh? M3;0OWlvcGmkaYTzJINmdGxiaX72ZZNqd25? NEXuXWszPDd{N{[2NC=>
Saos-2 NUi4R5BYTnWwY4Tpc44hSXO|YYm= NWLMNG5{PTBizszN NVrnbVJOPDhiaB?= M3\hb2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> MYWyOFczPzZ4MB?=
MG-63 NYX0OYRsTnWwY4Tpc44hSXO|YYm= MVy1NEDPxE1? NVPJcpplPDhiaB?= NX\qUVVQUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? MX2yOFczPzZ4MB?=
SJSA-1 NXnMOHd4TnWwY4Tpc44hSXO|YYm= NFPvZVg2OCEQvF2= MmC2OFghcA>? NXj4OpBOUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? M3HMWlI1PzJ5Nk[w
Saos-2 M2PiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;vS|UxKM7:TR?= M1TPOFQ5KGh? M{H5RWlvcGmkaYTzJINmdGxidnnhZoltcXS7 MnHXNlQ4Ojd4NkC=
MG-63 NUS1ZXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG1NEDPxE1? MVK0PEBp M{PNWGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NI\4coEzPDd{N{[2NC=>
SJSA-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qye|UxKM7:TR?= MXO0PEBp NYPxd3JqUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NWX4SXY6OjR5Mke2OlA>
FaDu M2DEU2Z2dmO2aX;uJGF{e2G7 NXXVWZhXPSEQvF2= MVeyOEBp NGXiVJRFVVOR NGexR|FT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> MYGyOFY{OTF2Nx?=
EMT6 MVPGeY5kfGmxbjDBd5NigQ>? MmnoOUDPxE1? NYLLVpN6OjRiaB?= MYDEUXNQ NIC3cVNT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NGq5UYczPDZ|MUG0Oy=>
HCT116 NFvuWmhHfW6ldHnvckBCe3OjeR?= M2fVTlUh|ryP MnLaNlQhcA>? MlS3SG1UVw>? NUO5TnBMWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> Mn2wNlQ3OzFzNEe=
U87 MoTpSpVv[3Srb36gRZN{[Xl? Ml\wOUDPxE1? MX:yOEBp M2rXWmROW09? MU\S[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= M4DLSFI1PjNzMUS3
GBM MmjIRZBweHSxc3nzJGF{e2G7 NYfEe|l6Os7:TR?= MWG0PIg> M1S0VWROW09? MXXpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5 M2O3SVI1PTByNEmy
BON MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2xMVXPxE1? M3rFU|czcA>? M4jtb4Rm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> M2TF[lI1PDR|NUKz
BON M1u2SmFxd3C2b4Ppd{BCe3OjeR?= NUjv[mNxOS13zszN MYOyOIg> MXfpcoNz\WG|ZYOgZZBweHSxc3nz NX\MN5c5OjR2NEO1NlM>
H1975 NEPnTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDrW|AxNjNvOT62{txO M2nXW|czcA>? M4P4RWROW09? M3\Yb2lEPTB;MT6zPFXPxE1? NITNbnEzPDN|N{i0Oi=>
H1975 MlXrRZBweHSxc3nzJGF{e2G7 NWr6U25NOs7:TR?= M4HlXVI1cA>? NVHqZYxMTE2VTx?= NGfPV|RqdmO{ZXHz[ZMh[XCxcITvd4l{KHKjdHWgd4lodmmoaXPhcpRtgQ>? MWmyOFM{Pzh2Nh?=
T-ALL NF\KR2VCeG:ydH;zbZMhSXO|YYm= NULnbGNL[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l NYrwTINGOjRib4KgOFhp NGHvclhFVVOR M1:5dIFn\mWldIOgeIhmKFCLM1ugdIF1cHejeTDpckBVNUGOTDDj[YxtKGyrbnXz M{nDNlI1OzFyN{O2
BCR-ABL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILZVXAxNjJ3LUGw{txO NGO0Z4w1\A>? NH\EeId{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w M{jVRVI1OjR2NkGy
LC-1/SQSF MoXjSpVv[3Srb36gRZN{[Xl? NYrM[lVyO87:TR?= M4mzRlI1cA>? MXXEUXNQ NVvrRnM{\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt MlXUNlM6QDByOUO=
Primary CLL cells MnLGRZBweHSxc3nzJGF{e2G7 MYqxMVEx|ryP MnS3OFhp MVTpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz M4K4d|I{QDVyOEC3
Primary CLL cells MX3LbY5ie2ViQYPzZZk> MonhNu69VQ>? MmLtN|BucW5? MYfk[YNz\WG|ZXSgVGk{UyCjY4Tpeol1gQ>? NILnemUzOzh3MEiwOy=>
Primary CLL cells M1XrXmN6fG:2b4jpZ{BCe3OjeR?= MVSy{txO MVSyOIg> MULpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 MYSyN|g2ODhyNx?=
human NSCLC cell lines M4\tWWFxd3C2b4Ppd{BCe3OjeR?= NFniW2gxNjF{NT20{txO Mm[wNlRp MXvEUXNQ NUmzbHNUUUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> MV2yN|U3OjR5Mh?=
human HCC cell lines M1fvXWNmdGxidnnhZoltcXS7IHHzd4F6 M1H3cVAvODB3LUJOwG0> M1;oXlQ5cA>? MXHJR|UxRTIQvF2= Ml7rNlM1QDl7OUm=
Huh7 MoLTT4lv[XOnIFHzd4F6 MV2x{txO M3rCOlQ5cA>? Mni0d4lodmoxrJHjZY51dHlicnXkeYNmeyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0 MkHYNlM1QDl7OUm=
SK-HEP1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPENU0zOM7:TR?= NETyV4c4Omh? NWHtdpVCTE2VTx?= MnPnTWM2OO,:nEJOwG0> MXeyN|Q4QTF|Nh?=
786-0 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXji[2lIOS1{MN88US=> NITkUnQ4Omh? NVjxVVNPTE2VTx?= MUDJR|Ux97zeMd88US=> NFeyeVkzOzR5OUGzOi=>
JVM2 MV7DfZRwfG:6aXPpeJkh[XO|YYm= NVftW2pmOC5{LUKw{txO M3zvZVczcA>? MVPEUXNQ M3S5WWlEPTB;MD65{txO Mnf0NlMzOzh4M{m=
EHEB Moi3R5l1d3SxeHnjbZR6KGG|c3H5 NVfDU2l4OC5{LUKw{txO MVO3Nog> M{LWTmROW09? NWjHXnQ3UUN3ME2wMlfPxE1? MV2yN|I{QDZ|OR?=
MEC2 MnztR5l1d3SxeHnjbZR6KGG|c3H5 MX:wMlIuOjEQvF2= NWL0RndqPzKq MWfEUXNQ MY\JR|UxRTBwN988US=> MnP2NlMzOzh4M{m=
primary B-CLL lymphocytes MWfBdI9xfG:|aYOgRZN{[Xl? MoDDTWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? MkjzNlRp NUjRcGNUTE2VTx?= MontTWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=> M3H3elI{OjN6NkO5
primary B-CLL lymphocytes NIjmb4hMcW6jc3WgRZN{[Xl? M{PK[WlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? MmjsNlRp MVPpcohq[mm2czDwO|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?= M{fN[FI{OjN6NkO5
human NSCLC M4rM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPxW2QxNjVvMt88US=> M{fLSVczcA>? M{ntdmlEPTB;Md88US=> Mn[1NlI4QDF|OUO=
human NSCLC NEG5fJhMcW6jc3WgRZN{[Xl? M4jjblHPxE1? MUmyOIg> NYTwTIR5cW6qaXLpeJMhfGinIFHreE9uXE:UIIPp[45idGmwZzDwZZRpf2G7IHH0JFNpKGGodHXyJJRz\WG2bXXueC=> Ml\mNlI4QDF|OUO=
Y1 cell line NXn1eWJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\HXFAvOc7:TT:x{txO NE\XWmYzPGh? NUjZcWJPTE2VTx?= M4TvV4lvcGmkaYTzJFYx97zHIHPlcIwhfmmjYnnsbZR6KGmwIF35Z{1U[3S{LYTyZY5{\mWldHXkJINmdGy| M{G1cFIzPjl{OUC0
PIK3CA-mutant MCF7 NGTDOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[wfGJRT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= MXW3Nog> NWHMVXRWT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= NFTSTXUzOjZ3M{m2Oy=>
PIK3CA-mutant MCF7 MnPsT4lv[XOnIFHzd4F6 MWLJR|UxRTFzNNMxN45O M2HrdFczcA>? NFvvW4xKSzVyPUGxOOKyO26PIHnuJJJm\HWlaX7nJGFsfCCyaH;zdIhwenmuYYTpc44hdGW4ZXzz NH3MTmUzOjZ3M{m2Oy=>
MCF7-myr-Akt MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXhOJhTT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= NVKzVIsxPzKq NVq0S5NJT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= Mo\nNlI3PTN7Nke=
colon cancer cell lines NWfIXFRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjMfWMxNTFyzszN MnzMO|Jp NXn3b2QxTE2VTx?= NVPXc48yUUN3ME2x{txO NVzrSIttOjJ3NEO4OVc>
gastric cancer cell lines NG\FZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7icFZqOC1zMN88US=> M2W0TlczcA>? Moe5SG1UVw>? MofyTWM2OD1{LUZOwG0> MX2yNlU1Ozh3Nx?=
HCT-116/HT-29/MKN-45 NGXrOXVCeG:ydH;zbZMhSXO|YYm= M1jHdFLPxE1? MoLaOFhp NELYZ4d{cGmodDDpckBIOiCyaHHz[S=> NHvkVXIzOjV2M{i1Oy=>
HT-29 and HCT-116 NHHnXnNE[XOyYYPlJIF{e2G7 M2TjfVXPxE1? MV6yOIg> MVLpcoR2[2W|IHPhd5Bie2ViYXP0bZZqfHl? MX:yNlU1Ozh3Nx?=
MM cell lines NWDpXGo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3NVDPxE1? NFj0XHUzPGh? NEnDbHNFVVOR NEjYUpZKSzVyII\hdolmeyCjbX;u[{BlcW[oZYLlcpQh[2WubDDsbY5meyCrbjD0bY1mKGGwZDDkc5NmKGSncHXu[IVv[2V? NVnkXWlDOjJ{MEe0PFU>
ARP-1 M1r3O2Fxd3C2b4Ppd{BCe3OjeR?= M333eVEx|ryP M3jzOlI1cA>? NIjFS29FVVOR NHrWdYFqdmS3Y3XzJG1OKGOnbHygZZBweHSxc3nzJJRpem:3Z3igZ4F{eGG|ZTDhZ5RqfmG2aX;u NH\5RXIzOjJyN{S4OS=>
SNU-601 M1LrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\6dnh{PzKq MmPkSG1UVw>? NWrhOFgyUUN3ME2wMlgyPsLzMD6wOlPPxE1? NFzS[WIzOjF3OUixOC=>
SNU-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKcINvPzKq NYHrUo5sTE2VTx?= M3vLZmlEPTB;MT6wPFLDuTBwMEK4{txO NFnvO2gzOjF3OUixOC=>
SNU-668 NFHZemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjXO|Jp NEHsXm9FVVOR MYnJR|UxRTFwNUe5xtExNjB5NN88US=> MmnxNlIyPTl6MUS=
AGS M2PSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDNO4M4Omh? MXfEUXNQ M2\GPWlEPTB;MT63NVTDuTBwMUG3{txO NXvLdVVDOjJzNUm4NVQ>
SNU-216 M1XkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;Q[XY4Omh? NGPwbFNFVVOR NELQZ3lKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? MX:yNlE2QThzNB?=
SNU-5 M2HDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXlO|Jp MYPEUXNQ NY\4TXRuUUN3ME2xMlM2OcLzMD6wPVHPxE1? NUXBWnlJOjJzNUm4NVQ>
SNU-638 M1PwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PPdFczcA>? NW\6ZnExTE2VTx?= MWLJR|UxRTJwMkiyxtExNjB3M988US=> MlT6NlIyPTl6MUS=
SNU-16 NEDheVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm3Nog> M3zXZmROW09? NV3lWINzUUN3ME2xMlU4O8LzMD6wNFHPxE1? M1;2WVIzOTV7OEG0
SNU-484 NWPmPGNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jCUFczcA>? MWTEUXNQ MVzJR|UxRTFwN{K4xtExNjB2Nd88US=> NX3tXoFEOjJzNUm4NVQ>
SNU-620 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv6T3k4Omh? MlraSG1UVw>? MXTJR|UxRTJwOUO5xtExNjByMd88US=> MlfPNlIyPTl6MUS=
SNU-719 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG0O|Jp MWPEUXNQ MVPJR|UxRTNwMEO3xtExNjB|Mt88US=> M4m1NVIzOTV7OEG0
glioma cell lines NEXKO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVy3Nog> M3\3fWlEPTB;MT2y{txO M{e1TVIzODZ3MEiw
U87 MnzQRZBweHSxc3nzJGF{e2G7 MUCy{txO MYW3Nog> NYe3SFJscW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM> NYTrOGpkOjJyNkWwPFA>

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Completed c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9, 2014 Phase 1|Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT02756247 Recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active, not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID